INO— INOVIO PHARMACEUTICALS, INC.

MaterialsBiotechnology$55M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue from collaborative arrangement	$65K-70.0%	$218K-73.8%	$832K-91.9%	$10.3M
Research and development	$54.2M-28.3%	$75.6M-12.8%	$86.7M-53.8%	$187.7M
General and administrative	$32.7M-11.7%	$37.0M-22.2%	$47.6M-47.2%	$90.2M
Total operating expenses	$86.9M-22.8%	$112.6M-22.2%	$144.8M-47.9%	$277.8M
Loss from operations	-$86.8M+22.8%	-$112.4M+21.9%	-$143.9M+46.2%	-$267.6M
Interest income	$2.4M-49.2%	$4.8M-41.4%	$8.1M+70.1%	$4.8M
Interest expense	$0+100.0%	-$178K+85.5%	-$1.2M+2.5%	-$1.3M
Change in fair value of common stock warrant liabilities	$493K-82.4%	$2.8M	—	—
Gain (loss) on investment in affiliated entity	$490K+142.0%	-$1.2M-250.9%	$773K+140.7%	-$1.9M
Net unrealized gain on available-for-sale equity securities	$1.1M-46.3%	$2.1M-64.5%	$5.9M+174.6%	-$7.8M
Other expense, net	-$2.6M+16.5%	-$3.2M+32.9%	-$4.7M-22.0%	-$3.9M
Net loss	-$84.9M+20.8%	-$107.3M+20.6%	-$135.1M+51.7%	-$279.8M
Basic (in USD per share)	-$1.81+54.2%	-$3.95+35.1%	-$6.09+56.7%	-$14.07
Diluted (in USD per share)	-$1.81+54.2%	-$3.95+35.1%	-$6.09+56.7%	-$14.07
Basic (in shares)	46.9M+72.6%	27.2M+22.5%	22.2M-90.7%	238.6M
Diluted (in shares)	46.9M+72.6%	27.2M+22.5%	22.2M-90.7%	238.6M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 16 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.